Now that the strategic manufacturing agreement with AVCN is 'expanded' we can now logically conclude that LABS had in the past a 'strategic manufacturing agreement' with Avicanna. Expansion beyond the South American market where Avicanna is predominantly present would simply either mean North America and/or the EU to explain the "expanded" portion of AVCN's strategic manufacturing agreement with LABS. Drug approvals in those markets, starting with commercialization of Trunerox will bring LABS into profitability or like the CEO said, 'if only one of these are approved it will change the face of the company'.
I will be conservative and out of the over 20 clinical trials LABS is involved with I will give a 20% success rate for Phase 3, meaning 4 more new drugs would make it to commercialization phase.
LABS has deleveraged their balance sheet, debt free, and is not encumbered with servicing any debt. This means any incremental revenue will convert quickly to positive profits/EPS at the bottom line.
We can now look at the other end of the scale at WEED, negotiating a debt reduction plan at around 95 cents on the dollar and having to issue more stock, diluting shareholders further, basically trying to keep their heads above water while facing a delisting on NASDAQ.